Microsatellite Instability in Urine: Breakthrough Method for Bladder Cancer Identification

Area of Science:

• Oncology
• Urology
• Molecular Biology

Background:

• Bladder cancer (BC) is a prevalent urinary system neoplasm with high recurrence rates, leading to significant patient costs.
• Traditional cystoscopy for BC detection and surveillance is invasive, while non-invasive methods like cytology lack sufficient sensitivity.
• There is a critical need for effective, non-invasive diagnostic and monitoring strategies for bladder cancer.

Purpose of the Study:

• To review the evidence for using microsatellite instability (MSI) in exfoliated bladder tumor cells (EBTCs) found in urine for bladder cancer detection.
• To evaluate the potential of MSI as a non-invasive biomarker for bladder cancer identification and treatment guidance.
• To highlight the importance of establishing clinical guidelines for the standardized application and validation of MSI testing in bladder cancer management.

Main Methods:

• Literature review focusing on studies identifying microsatellite instability (MSI) in exfoliated bladder tumor cells (EBTCs) within urine samples.
• Analysis of existing evidence regarding the sensitivity and specificity of MSI detection for bladder cancer.
• Exploration of the role of MSI in tumor cell detection and its potential for guiding targeted therapies.

Main Results:

• Microsatellite instability (MSI) has emerged as a promising biomarker for detecting bladder cancer (BC) in urine samples.
• Identification of MSI in exfoliated bladder tumor cells (EBTCs) offers a potential non-invasive alternative to traditional methods.
• The analysis supports MSI's utility in early cancer detection and potentially guiding targeted treatment strategies.

Conclusions:

• Microsatellite instability (MSI) in urine holds significant potential as a non-invasive tool for bladder cancer (BC) detection and surveillance.
• Standardized clinical guidelines are essential to validate and implement MSI testing effectively in oncological practice.
• Further research and validation are crucial to establish MSI as a reliable biomarker in routine bladder cancer management.